These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 2345839)

  • 41. A mixed method pilot study: the researchers' experiences.
    Secomb JM; Smith C
    Contemp Nurse; 2011 Aug; 39(1):31-5. PubMed ID: 21955264
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacodynamic analysis of sparse data from concentration- and effect-controlled clinical trials guided by a pilot study. An investigation by simulations.
    Fullerton T; Forrest A; Levy G
    J Pharm Sci; 1996 Jun; 85(6):600-7. PubMed ID: 8773956
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pilot randomized trials: is there a need?
    Jeray KJ; Tanner SL
    J Bone Joint Surg Am; 2012 Jul; 94 Suppl 1():15-8. PubMed ID: 22810441
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A tutorial on pilot studies: the what, why and how.
    Thabane L; Ma J; Chu R; Cheng J; Ismaila A; Rios LP; Robson R; Thabane M; Giangregorio L; Goldsmith CH
    BMC Med Res Methodol; 2010 Jan; 10():1. PubMed ID: 20053272
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Re-evaluating design specifications of longitudinal clinical trials without unblinding when the key response is rate of change.
    Shih WJ; Gould AL
    Stat Med; 1995 Oct; 14(20):2239-48. PubMed ID: 8552900
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sample size considerations for studies of intervention efficacy in the occupational setting.
    Lazovich D; Murray DM; Brosseau LM; Parker DL; Milton FT; Dugan SK
    Ann Occup Hyg; 2002 Mar; 46(2):219-27. PubMed ID: 12074031
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sample size re-estimation incorporating prior information on a nuisance parameter.
    Mütze T; Schmidli H; Friede T
    Pharm Stat; 2018 Mar; 17(2):126-143. PubMed ID: 29181869
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Blinded sample size re-estimation in superiority and noninferiority trials: bias versus variance in variance estimation.
    Friede T; Kieser M
    Pharm Stat; 2013; 12(3):141-6. PubMed ID: 23509095
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Statistical power in three-arm cluster randomized trials.
    Liu XS
    Eval Health Prof; 2014 Dec; 37(4):470-87. PubMed ID: 23908381
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sample size re-estimation in cluster randomization trials.
    Lake S; Kammann E; Klar N; Betensky R
    Stat Med; 2002 May; 21(10):1337-50. PubMed ID: 12185888
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Blinded sample size reestimation with count data: methods and applications in multiple sclerosis.
    Friede T; Schmidli H
    Stat Med; 2010 May; 29(10):1145-56. PubMed ID: 20146203
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Project management lessons learned from the multicentre CYCLE pilot randomized controlled trial.
    McCaskell DS; Molloy AJ; Childerhose L; Costigan FA; Reid JC; McCaughan M; Clarke F; Cook DJ; Rudkowski JC; Farley C; Karachi T; Rochwerg B; Newman A; Fox-Robichaud A; Herridge MS; Lo V; Feltracco D; Burns KE; Porteous R; Seely AJE; Ball IM; Seczek A; Kho ME
    Trials; 2019 Aug; 20(1):532. PubMed ID: 31455384
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Progression criteria in trials with an internal pilot: an audit of publicly funded randomised controlled trials.
    Herbert E; Julious SA; Goodacre S
    Trials; 2019 Aug; 20(1):493. PubMed ID: 31399148
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sample size recalculation in multicenter randomized controlled clinical trials based on noncomparative data.
    Harden M; Friede T
    Biom J; 2020 Sep; 62(5):1284-1299. PubMed ID: 32128868
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Improving interim decisions in randomized trials by exploiting information on short-term endpoints and prognostic baseline covariates.
    Van Lancker K; Vandebosch A; Vansteelandt S
    Pharm Stat; 2020 Sep; 19(5):583-601. PubMed ID: 32248662
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effects of alternative study designs on the power of community randomized trials: evidence from three studies of human immunodeficiency virus prevention in East Africa.
    Todd J; Carpenter L; Li X; Nakiyingi J; Gray R; Hayes R
    Int J Epidemiol; 2003 Oct; 32(5):755-62. PubMed ID: 14559745
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Implementing a decision-theoretic design in clinical trials: why and how?
    Palmer CR; Shahumyan H
    Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The importance of piloting an RCT intervention.
    Feeley N; Cossette S; Côté J; Héon M; Stremler R; Martorella G; Purden M
    Can J Nurs Res; 2009 Jun; 41(2):85-99. PubMed ID: 19650515
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prophylaxis of Thromboembolism in Critical Care (PROTECT) Trial: a pilot study.
    Cook DJ; Rocker G; Meade M; Guyatt G; Geerts W; Anderson D; Skrobik Y; Hebert P; Albert M; Cooper J; Bates S; Caco C; Finfer S; Fowler R; Freitag A; Granton J; Jones G; Langevin S; Mehta S; Pagliarello G; Poirier G; Rabbat C; Schiff D; Griffith L; Crowther M; ;
    J Crit Care; 2005 Dec; 20(4):364-72. PubMed ID: 16310609
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A practical Bayesian stepped wedge design for community-based cluster-randomized clinical trials: The British Columbia Telehealth Trial.
    Cunanan KM; Carlin BP; Peterson KA
    Clin Trials; 2016 Dec; 13(6):641-650. PubMed ID: 27430710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.